Download Files:
NNZ 2591
$176 – $3,320
Products Details
Product Description
– NNZ 2591 is a synthetic analogue of a small peptide of cyclic glycine proline (cGP). NNZ 2591 shows orally active and cross the blood-brain barrier. NNZ 2591 shows neuroprotective after ischemic brain injury. NNZ 2591 improves motor function in a rat model of Parkinson’s disease. NNZ 2591 has the potential for the research of ischemic brain injury and angelman syndrome[1][2][3].
Web ID
– HY-148195
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Neuroscience-Neurodegeneration
Molecular Formula
– C10H14N2O2
References
– [1]Guan J, et al. NNZ-2591, a novel diketopiperazine, prevented scopolamine-induced acute memory impairment in the adult rat. Behav Brain Res. 2010 Jul 11;210(2):221-8.|[2]Guan J, et al. Peripheral administration of a novel diketopiperazine, NNZ 2591, prevents brain injury and improves somatosensory-motor function following hypoxia-ischemia in adult rats. Neuropharmacology. 2007 Nov;53(6):749-62.|[3]Copping NA, et al. Emerging Gene and Small Molecule Therapies for the Neurodevelopmental Disorder Angelman Syndrome. Neurotherapeutics. 2021 Jul;18(3):1535-1547.
CAS Number
– 847952-38-9
Molecular Weight
– 194.23
Compound Purity
– 99.98
SMILES
– C=CC[C@@]12N(CCC2)C(CNC1=O)=O
Clinical Information
– No Development Reported
Research Area
– Neurological Disease
Solubility
– DMSO : 18.75 mg/mL (ultrasonic)
Target
– Others
Pathway
– Others
Product type
– Peptides
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
